In addition, the study highlighted the therapeutic abilities of IL-6 inhibitors, including siltuximab and tocilizumab, in addressing autoimmune diseases, cytokine release syndrome, and hyperinflammation induced by COVID-19. Here, IL6 is linked to autoimmune disease.